Literature DB >> 11373353

Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats.

Haruhito Azuma1, Shiro Takahara1, Kunio Matsumoto2, Naotsugu Ichimaru1, Jing Ding Wang1, Toshiki Moriyama3, Ana-Maria Waaga4, Masaya Kitamura1, Yoshinori Otsuki5, Akihiko Okuyama1, Yoji Katsuoka1, Anil Chandraker4, Mohamed H Sayegh4, Toshikazu Nakamura2.   

Abstract

Long-term renal isografts in humans and laboratory animals exhibit features similar to those of chronic allograft nephropathy (CAN), indicating that antigen-independent factors, such as acute renal ischemia, are likely to be involved in the development of CAN. Hepatocyte growth factor (HGF) has been demonstrated to play a renotropic role in renal regeneration and protection from acute ischemic injury. This study was thus conducted to investigate the effect of HGF on the development of CAN, using an established rat model. HGF was administered daily (100 microg/d, intravenously) for 4 wk after engraftment. Control animals received saline solution. Allografts from control animals exhibited early evidence of severe structural collapse and necrotic cell death in the proximal tubules and outer medulla, with mononuclear cell infiltration, within 1 wk after engraftment. This was followed by sequential upregulation of adhesion molecules and cytokines, accompanied by dense macrophage infiltration. Fibrogenic events, as indicated by marked increases in transforming growth factor-beta1 expression and the accumulation of smooth muscle alpha-actin, occurred during the same period. Control animals ultimately developed features typical of CAN, with functional deterioration and severe histologic changes; a survival rate of 50.6% by 32 wk was observed. In contrast, remarkably little early injury and no late fibrogenic events were observed for the HGF-treated group. All treated animals survived, with well preserved graft function, during the 32-wk follow-up period. These results indicate that renal protection and recovery from early allograft injury with HGF treatment greatly contribute to a reduction of susceptibility to the subsequent development of CAN in a rat model. The potential application of HGF in the prevention of CAN warrants further attention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11373353     DOI: 10.1681/ASN.V1261280

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  16 in total

1.  Diminished met signaling in podocytes contributes to the development of podocytopenia in transplant glomerulopathy.

Authors:  Putri A Agustian; Mario Schiffer; Wilfried Gwinner; Irini Schäfer; Katharina Theophile; Friedrich Modde; Clemens L Bockmeyer; Jana Traeder; Ulrich Lehmann; Anika Grosshennig; Hans H Kreipe; Verena Bröcker; Jan U Becker
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria.

Authors:  Chunsun Dai; Moin A Saleem; Lawrence B Holzman; Peter Mathieson; Youhua Liu
Journal:  Kidney Int       Date:  2010-03-10       Impact factor: 10.612

3.  Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys.

Authors:  Shinya Mizuno; Toshikazu Nakamura
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

4.  Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7.

Authors:  Manasi N Shukla; Jane L Rose; Rabindranath Ray; Kira L Lathrop; Anuradha Ray; Prabir Ray
Journal:  Am J Respir Cell Mol Biol       Date:  2008-11-06       Impact factor: 6.914

Review 5.  Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Authors:  Arjang Djamali; Millie Samaniego
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

6.  Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.

Authors:  Philip J O'Connell; Weijia Zhang; Madhav C Menon; Zhengzi Yi; Bernd Schröppel; Lorenzo Gallon; Yi Luan; Ivy A Rosales; Yongchao Ge; Bojan Losic; Caixia Xi; Christopher Woytovich; Karen L Keung; Chengguo Wei; Ilana Greene; Jessica Overbey; Emilia Bagiella; Nader Najafian; Milagros Samaniego; Arjang Djamali; Stephen I Alexander; Brian J Nankivell; Jeremy R Chapman; Rex Neal Smith; Robert Colvin; Barbara Murphy
Journal:  Lancet       Date:  2016-07-22       Impact factor: 79.321

7.  Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling.

Authors:  Myrto Giannopoulou; Chunsun Dai; Xiaoyue Tan; Xiaoyan Wen; George K Michalopoulos; Youhua Liu
Journal:  Am J Pathol       Date:  2008-05-23       Impact factor: 4.307

Review 8.  Late kidney allograft loss: what we know about it, and what we can do about it.

Authors:  Anthony M Jevnikar; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

9.  Human hepatocyte growth factor (hHGF)-modified hepatic oval cells improve liver transplant survival.

Authors:  Zhu Li; Juan Chen; Li Li; Jiang-Hua Ran; Xue-Hua Li; Zhi-Heng Liu; Gui-Jie Liu; Yan-Chao Gao; Xue-Li Zhang; Hiu-Dong Sun
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  Genomic meta-analysis of growth factor and integrin pathways in chronic kidney transplant injury.

Authors:  Amrita Dosanjh; Elizabeth Robison; Tony Mondala; Steven R Head; Daniel R Salomon; Sunil M Kurian
Journal:  BMC Genomics       Date:  2013-04-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.